Ideas & Impact › Resources › Accelerating Access to Optimal Child-Friendly Antiretroviral Formulations

While clinical trials have demonstrated the benefits of Dolutegravir (DTG) and Lopinavir-Ritonavir (LPV/r) over Nevirapine (NVP)-based regimens, many children are still on NVP-based regimens. Even when LPV/r syrup is available, it is poorly tolerated by children and difficult to store due to its cold chain requirement. This brief provides an overview of EGPAF’s continued work under Unitaid’s POC EID grant to accelerate sustainable access to optimal pediatric ARV formulations in five implementing countries, Côte d’Ivoire, Eswatini, Lesotho, Mozambique and Zimbabwe.

Explore Related Resources

Search More Resources

Fact Sheets

The Pediatric Treatment Gap

Published March 2026

Topics:

HIV,

Pediatric HIV

Countries:

Global

Issue Briefs

Accelerating Progress to Ending Pediatric HIV

Published March 2026

We are at a critical inflection point for children affected by HIV. In 2024 alone, 120,000 children were newly infected, and, without timely treatment, half of HIV positive infants will not reach their second birthday. Children remain left behind—a child with HIV is 6 times more likely to die than an adult without timely diagnosis. […]

Topics:

HIV,

Pediatric HIV

Countries:

Global

Resource

Protecting Lives, Sustaining Progress

Published March 2026

The following landscape analysis of maternal and child health, HIV prevention, diagnosis, and treatment, and the historic strength of U.S. leadership in global aid provides an overview of these key areas of global health and recommendations for U.S. Congressional engagement and prioritization.

Topics:

Advocacy,

Children,

Global Health Security,

Health System Strengthening,

HIV,

Maternal and Child Health,

Mothers and Infants,

Women

Countries:

Global,

United States